Encompass Health (EHC)
(Delayed Data from NYSE)
$96.75 USD
+1.49 (1.56%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $96.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Average Brokerage Rating
Current ABR | 1.08 |
ABR (Last week) | 1.08 |
# of Recs in ABR | 12 |
Average Target Price | $100.91 |
LT Growth Rate | 15.80% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 48 of 253 |
Current Quarter EPS Est: | 0.94 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 10 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.08 | 1.08 | 1.08 | 1.09 | 1.10 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | UBS | Aj Rice | Not Available | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/6/2024 | Raymond James | John W Ransom | Strong Buy | Strong Buy |
8/6/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
8/5/2024 | William Blair | Jared Haase | Strong Buy | Strong Buy |
7/15/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
7/10/2024 | SVB Securities | Whit Mayo | Not Available | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/22/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/25/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.